Please login to the form below

Not currently logged in
Email:
Password:

Interlace realigns business to focus on communications

Sells off regulatory and pharmacovigilance interests

Interlace Global

Interlace Global Group has sold its regulatory and pharmacovigilance business Quantum Medical to Spectrum Regulatory Solutions, and will concentrate on its three communications agencies; Wells Healthcare, Interlace Communications and US-based WHC Inc.

“Following a strategic review of our global business we've made the decision to focus our activities specifically in the fast developing eMedia field where we have unique digital training and interactive e-learning strengths that are valued by our clients,” said Interlace owner and group managing director Mark Forbes Irving.

Focusing on communications will, he said 'provide an offering that complements our traditional areas of recognised strength: strategic consultancy, publication and communications planning, scientific writing, advocacy development, live events, strategic advisory boards, creative services, clinical trial support, and bespoke market access programmes'.

Speaking to PMLiVE, Forbes Irving explained that the first priorities of the realigned Interlace are “the release of our innovative digital training technology and learning platforms to existing and new clients and the launch of a new suite of digital offerings developed by our in-house eMedia unit”.

Interlace will also focus on accelerating the delivery of “patient-centric” communication programmes to complement clients' shifts from “product-centric” to “patient-centric” strategic communication initiatives, he said.

Forbes Irving also told PMLiVE that Interlace plans to launch a fourth agency, IGC Inc, during the fourth quarter of 2013. It will support the group's new US business.

Having been bought by Spectrum, Quantum now belongs to Zaicom International, which already owns Zaicom Healthcare, Zaicom Research Plus and Zaicom Consulting.

“The addition of Quantum will make us the 'go to' agency for all regulatory requirements and allow us to optimise our global presence,” said Zaicom International CEO, Graeme Chrystal.

11th September 2013

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics